Fairmount Funds Management LLC 13D and 13G filings for Inhibikase Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 3:45 pm Purchase |
2024-12-31 | 13G | Inhibikase Therapeutics, Inc. IKT |
Fairmount Funds Management LLC | 7,018,575 9.900% |
398,264 (+6.02%) |
Filing |
| 2024-10-17 7:00 pm Purchase |
2024-10-09 | 13G | Inhibikase Therapeutics, Inc. IKT |
Fairmount Funds Management LLC | 6,620,311 9.900% |
6,620,311 (New Position) |
Filing |